{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:36:15Z","timestamp":1793147775957,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Menarini Stemline Italy S.r.l."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15083-y","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:15:50Z","timestamp":1761902150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework"],"prefix":"10.1186","volume":"25","author":[{"given":"Mario","family":"Boccadoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Bombaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cafro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caimmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Canali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"La Malfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mercati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Montefusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Riccaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"3","key":"15083_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"key":"15083_CR2","unstructured":"AIOM, AIRTUM. I numeri del cancro in Italia. 2020. https:\/\/www.registri-tumori.it\/cms\/pubblicazioni\/i-numeri-del-cancro-italia-2020"},{"key":"15083_CR3","unstructured":"AIOM. Linee Guida Mieloma. 2017. https:\/\/www.aiom.it\/mieloma-2017\/"},{"issue":"1","key":"15083_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/EDBK_349603","volume":"42","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am Soc Clin Oncol Educational Book. 2022;42(1):643\u201354.","journal-title":"Am Soc Clin Oncol Educational Book."},{"issue":"5","key":"15083_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers15051558","volume":"15","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Queiz\u00e1n JA, B\u00e1rez A, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers. 2023;15(5):1558.","journal-title":"Cancers"},{"issue":"1","key":"15083_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","volume":"24","author":"LN Gordan","year":"2024","unstructured":"Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, et al. Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study. Clin Lymphoma Myeloma Leuk. 2024;24(1):55\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"15083_CR7","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"11","key":"15083_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"15083_CR9","doi-asserted-by":"publisher","first-page":"10150","DOI":"10.1182\/blood-2022-163335","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar SK, Moreau P, Bahlis NJ, Facon T, Plesner T, Orlowski RZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia study. Blood. 2022;140(Supplement 1):10150\u20133.","journal-title":"Blood"},{"key":"15083_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.07.001","author":"M Boccadoro","year":"2025","unstructured":"Boccadoro M, Mercati R, Vassallo C, Canali B, Fiorentino F, Galeone C. Rising unmet need in multiple myeloma management after first-line treatment with drd: expected epidemiological evolution in Italy. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.07.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"15083_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2020000109","volume":"2020","author":"NWCJ van de Donk","year":"2020","unstructured":"van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology. 2020;2020(1):248\u201358.","journal-title":"Hematology"},{"key":"15083_CR12","unstructured":"EMA. EPAR Kyprolis. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kyprolis-h-c-3790-ii-0001-g-epar-assessment-report-variation_en.pdf"},{"key":"15083_CR13","unstructured":"EMA. EPAR Imnovid. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imnovid-h-c-2682-ii-0031-g-epar-assessment-report-variation_en.pdf"},{"key":"15083_CR14","unstructured":"EMA. EPAR Nexpovio. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/nexpovio-h-c-005127-ii-0001-g-epar-assessment-report_en.pdf"},{"key":"15083_CR15","unstructured":"Gazzetta Ufficiale. GU Serie Generale n.181 del 03-08-2024. 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2024-08-03%26;atto.codiceRedazionale=24A03950%26;elenco30giorni=false"},{"key":"15083_CR16","unstructured":"Gazzetta Ufficiale. GU Serie Generale n.270 del 29-10-2020. 2020. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2020-10-29%26;atto.codiceRedazionale=20A05749%26;elenco30giorni=false"},{"key":"15083_CR17","unstructured":"Gazzetta Ufficiale. GU Serie Generale n.298 del 22-12-2017. 2017. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2017-12-22%26;atto.codiceRedazionale=17A08556%26;elenco30giorni=false"},{"issue":"6","key":"15083_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. JCO. 2014;32(6):587\u2013600.","journal-title":"JCO"},{"issue":"5","key":"15083_CR19","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","volume":"28","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, et al. Impact of treatment sequencing on overall survival in patients with Transplant-Ineligible newly diagnosed myeloma. Oncologist. 2023;28(5):e263\u20139.","journal-title":"Oncologist"},{"issue":"3","key":"15083_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2023.100771","volume":"12","author":"C Jommi","year":"2023","unstructured":"Jommi C, Bertolani A, Armeni P, Costa F, Otto M. Pharmaceutical pricing and managed entry agreements: an exploratory study on future perspectives in Europe. Health Policy Technol. 2023;12(3):100771.","journal-title":"Health Policy Technol"},{"issue":"4","key":"15083_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jval.2017.10.001","volume":"21","author":"KD Marsh","year":"2018","unstructured":"Marsh KD, Sculpher M, Caro JJ, Tervonen T. The use of MCDA in HTA: great potential, but more effort needed. Value Health. 2018;21(4):394\u20137.","journal-title":"Value Health"},{"issue":"2","key":"15083_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","volume":"19","author":"K Marsh","year":"2016","unstructured":"Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kal\u00f3 Z, et al. Multiple criteria decision analysis for health care decision making\u2014emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(2):125\u201337.","journal-title":"Value Health"},{"issue":"1","key":"15083_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making\u2014an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1\u201313.","journal-title":"Value Health"},{"issue":"2","key":"15083_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejor.2011.09.019","volume":"217","author":"CA Bana e Costa","year":"2012","unstructured":"Bana e Costa CA, Carnero MC, Oliveira MD. A multi-criteria model for auditing a predictive maintenance programme. Eur J Oper Res. 2012;217(2):381\u201393.","journal-title":"Eur J Oper Res"},{"issue":"02","key":"15083_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1142\/S0219622012400068","volume":"11","author":"CA Bana e Costa","year":"2012","unstructured":"Bana e Costa CA, De Corte JM, Vansnick JC. MACBETH Int J Info Tech Dec Mak. 2012;11(02):359\u201387.","journal-title":"MACBETH Int J Info Tech Dec Mak"},{"issue":"1","key":"15083_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10726-012-9326-2","volume":"23","author":"CA Bana e Costa","year":"2014","unstructured":"Bana e Costa CA, Louren\u00e7o JC, Oliveira MD, Bana e Costa JC. A socio-technical approach for group decision support in public strategic planning: the Pernambuco PPA case. Group Decis Negot. 2014;23(1):5\u201329.","journal-title":"Group Decis Negot"},{"issue":"1","key":"15083_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ejor.2022.05.037","volume":"305","author":"CA Bana e Costa","year":"2023","unstructured":"Bana e Costa CA, Oliveira MD, Vieira ACL, Freitas L, Rodrigues TC, Bana e Costa J, et al. Collaborative development of composite indices from qualitative value judgements: the EURO-HEALTHY population health index model. Eur J Oper Res. 2023;305(1):475\u201392.","journal-title":"Eur J Oper Res"},{"issue":"1","key":"15083_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12955-019-1189-7","volume":"17","author":"F Gansen","year":"2019","unstructured":"Gansen F, Klinger J, Rogowski W. Mcda-based deliberation to value health states: lessons learned from a pilot study. Health Qual Life Outcomes. 2019;17(1):112.","journal-title":"Health Qual Life Outcomes"},{"key":"15083_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112595","volume":"246","author":"A Angelis","year":"2020","unstructured":"Angelis A, Linch M, Montibeller G, Molina-Lopez T, Zawada A, Orzel K, et al. Multiple criteria decision analysis for HTA across four EU member states: piloting the advance value framework. Soc Sci Med. 2020;246:112595.","journal-title":"Soc Sci Med"},{"issue":"1","key":"15083_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15083_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394.","journal-title":"Lancet Oncol"},{"issue":"10262","key":"15083_CR32","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373.","journal-title":"Lancet"},{"issue":"12","key":"15083_CR33","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/j.jval.2023.09.1979","volume":"26","author":"R Chapman","year":"2023","unstructured":"Chapman R, Xie R, Cheng YYM, Phelps CE, Marsh K, Thokala P. HTA296 applying continual stakeholder engagement to develop multi-criteria decision analysis (MCDA) for health technology assessment in major depressive disorder (MDD). Value Health. 2023;26(12):S377-8.","journal-title":"Value Health"},{"issue":"4","key":"15083_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"7","key":"15083_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","volume":"24","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324\u201331.","journal-title":"Drug Discov Today"},{"key":"15083_CR36","doi-asserted-by":"publisher","unstructured":"Bana e Costa CA, De Corte JM, Vansnick JC. On the Mathematical Foundations of MACBETH. In: Greco S, Ehrgott M, Figueira JR, editors. Multiple Criteria Decision Analysis: State of the Art Surveys [Internet]. New York, NY: Springer New York; 2016. pp. 421\u201363. Available from: https:\/\/doi.org\/10.1007\/978-1-4939-3094-4_11","DOI":"10.1007\/978-1-4939-3094-4_11"},{"issue":"2","key":"15083_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s41669-017-0048-x","volume":"2","author":"M Garau","year":"2018","unstructured":"Garau M, Hampson G, Devlin N, Mazzanti NA, Profico A. Applying a multicriteria decision analysis (MCDA) approach to elicit stakeholders\u2019 preferences in Italy: the case of obinutuzumab for Rituximab-Refractory indolent Non-Hodgkin lymphoma (iNHL). Pharmacoecon Open. 2018;2(2):153\u201363.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"15083_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.33393\/abtpn.2019.302","volume":"6","author":"C Jommi","year":"2019","unstructured":"Jommi C, Ravasio R. Il valore Di obinutuzumab per Il Trattamento in Prima linea Del Linfoma follicolare: un\u2019analisi basata Su approccio multicriteria decision analysis (MCDA). AboutOpen. 2019;6(1):78\u201385.","journal-title":"AboutOpen"},{"issue":"9","key":"15083_CR39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.healthpol.2021.06.008","volume":"125","author":"P Russo","year":"2021","unstructured":"Russo P, Carletto A, N\u00e9meth G, Habl C. Medicine price transparency and confidential managed-entry agreements in europe: findings from the EURIPID survey. Health Policy. 2021;125(9):1140\u20135.","journal-title":"Health Policy"},{"issue":"2","key":"15083_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/ejh.14223","volume":"113","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Engelhardt M, Leleu X, Mesa MG, Cavo M, Dimopoulos M, et al. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial. Eur J Haematol. 2024;113(2):242\u201352.","journal-title":"Eur J Haematol"},{"key":"15083_CR41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22:680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"15083_CR42","first-page":"2075","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano F, Cavo M, Niscola P, Caravita T, Efficace F. Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review. Support Care Cancer. 2018;26(7):2075\u201390.","journal-title":"Support Care Cancer"},{"issue":"9","key":"15083_CR43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/17474086.2019.1645005","volume":"12","author":"P Niscola","year":"2019","unstructured":"Niscola P, Scaramucci L, Efficace F. Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma. Expert Rev Hematol. 2019;12(9):703\u20135.","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"15083_CR44","doi-asserted-by":"publisher","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","volume":"149","author":"A Fleischer","year":"2023","unstructured":"Fleischer A, Zapf L, Allgaier J, Jordan K, Gelbrich G, Pryss R, et al. A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol. 2023;149(14):12897\u2013902.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"15083_CR45","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers15030955","volume":"15","author":"A Astarita","year":"2023","unstructured":"Astarita A, Mingrone G, Airale L, Cesareo M, Colomba A, Catarinella C, et al. Carfilzomib-based regimen and cardiotoxicity in multiple myeloma: incidence of cardiovascular events and organ damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. a real-life prospective study. Cancers. 2023;15(3):955.","journal-title":"Cancers"},{"issue":"9","key":"15083_CR46","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C, W\u00e4sch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy \u2013 incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA). Haematologica. 2018;103(9):1422\u201332.","journal-title":"Haematologica"},{"key":"15083_CR47","doi-asserted-by":"crossref","unstructured":"Kastritis E, Harvey R, Cranmer H, Bianco M, Fenu E, La Porte C, et al. Network Meta-Analysis of Randomized Trials in Relapsed\/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory. Blood. 2023;2(142):7424.","DOI":"10.1182\/blood-2023-180947"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15083-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:15:56Z","timestamp":1761902156000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15083"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15083-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.B., A.B., F.B., S.B., G.B., A.M.C., P.L.C., M.Cav., A.C., L.D.P., D.D., F.D.R., C.G., F.G., M.G., N.G., V.M., P.M., M.O., F.P., M.T.P., M.R., P.T., E.Z., and R.Z. received a professional fee to participate in the study by Menarini Stemline Italia S.r.l.At the time of project initiation and drafting of the paper, M.Cai., B.C., P.L.M., R.M., and F.F. were employed by IQVIA Italy, which receives professional service fees for a large number of activities in biopharma from a large number of sponsors, including Menarini Stemline Italia S.r.l.M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards of Janssen and GlaxoSmithKline; and has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. A.B. has served on the advisory boards of Janssen, Amgen, GlaxoSmithKline, and Pfizer. S.B. has received honoraria from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, and AbbVie; has served on the advisory boards of Bristol Myers Squibb, Janssen, Takeda, Pfizer, Stemline Therapeutics, and Oncopeptides; and has received consultancy fees from Sanofi. M.Cav. has received honoraria from Janssen, Celgene, Amgen, Bristol Myers Squibb, Takeda, AbbVie, Sanofi, and Adaptive Biotechnologies; and is a member of speakers\u2019 bureaus for Janssen and Celgene. L.D.P. has served on the advisory boards of AbbVie, Amgen, Celgene, and Janssen. F.G. has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, and Sanofi; has served on the advisory boards of Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Oncopeptides, Pfizer, Sanofi, AstraZeneca, and Kite, a Gilead company. P.M. has received honoraria from Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and GlaxoSmithKline; and has served on the advisory boards of Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Jazz, Sanofi, AbbVie, and GlaxoSmithKline. M.O. has received honoraria and served on the advisory boards of Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Sanofi, and Takeda. F.P. has participated in advisory boards and\/or received fees for presentations at meetings from Bristol Myers Squibb, Janssen, Menarini, Novartis, Sanofi, and Takeda. M.T.P. has received honoraria from Janssen, Bristol Myers Squibb, Amgen, Sanofi, GlaxoSmithKline, and Takeda; has served on the advisory boards of Janssen, Bristol Myers Squibb, Amgen, Sanofi, GlaxoSmithKline, Takeda, Roche, Oncopeptides, Pfizer, and Menarini; and has received support for attending meetings and\/or travel from Janssen, Bristol Myers Squibb, Amgen, Sanofi, and Takeda. E.Z. has received honoraria from Janssen, Bristol Myers Squibb, Amgen, and Takeda. R.Z. has served on the advisory boards of Janssen, Bristol Myers Squibb, Amgen, Sanofi, GlaxoSmithKline, Menarini, and Oncopeptides. All other authors declare no further competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1676"}}